key: cord-0782643-6bx4057h
authors: Mackey, Katherine; Kansagara, Devan; Vela, Kathryn
title: Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
date: 2020-08-26
journal: Ann Intern Med
DOI: 10.7326/l20-1068
sha: fddd738b321bac0dd483824217b137ca456b52c6
doc_id: 782643
cord_uid: 6bx4057h

nan

We searched MEDLINE (Ovid) weekly from 7 July to 3 August 2020 using the same search strategy as described in the original review (1). We did not limit the search by language. This search update yielded 67 results (de-duplicated), and after an independent dual-review process, we identified 2 new meta-analyses and 1 reestimated meta-analysis (2) (3) (4) , interim results from 1 randomized controlled trial (5), and 13 new observational studies (6 -18) . New Evidence Results of 2 meta-analyses found that angiotensinconverting enzyme inhibitor (ACEI) and angiotensin-receptor blocker (ARB) use was not associated with coronavirus disease 2019 (COVID-19) disease severity (2, 3) . In 1 of these metaanalyses of 9 primary studies with a total of 3936 patients with hypertension, use of ACEIs or ARBs was associated with a lower mortality in COVID-19 (2) . In the other meta-analysis of 15 studies of 7410 patients with hypertension, subgroup analysis found that ARB use, but not ACEI use, was associated with lower mortality (3). A third meta-analysis reestimated data from studies included in a prior review and found that exclusion of a retracted study by Mehra and colleagues did not change the prior review's finding of a lack of association with ACEI and ARB use and COVID-19 mortality (4, 19) .

In addition, interim findings from an ongoing randomized controlled trial (started in 2018) on the use of ramipril among patients with aortic stenosis treated with transcatheter aortic valve replacement found that the use of ramipril was not associated with the incidence or severity of COVID-19 (20). To our knowledge, this is the first study to report findings from a randomized controlled trial on the association between ACEI use and COVID-19.

We also identified 13 new observational studies (6 -18). One of these observational studies that was based on analysis of insurance data in Korea addressed our first key question regarding the use of ACEIs and ARBs and COVID-19 risk, finding that increased adherence to ACEI and ARB treatment was associated with a lower incidence of COVID-19 (10) . Twelve studies addressed our second key question about ACEI and ARB use and COVID-19 disease severity, and 11 of these studies found a lack of association with ACEIs or ARBs and more severe disease (6 -9, 11-13, 15-18) . Moreover, 3 of these 11 studies found that use of ACEIs or ARBs was associated with less severe COVID-19 illness (11, 16, 18) . The exception was a French study of 149 patients hospitalized with severe COVID-19 illness (defined by an oxygen saturation of 94% or less while the patient was breathing ambient air or receiving oxygen support), 44 of whom were receiving ACEIs or ARBs (14) . This study found that ACEI and ARB use was associated with a higher risk for acute kidney injury. However, this study did not examine whether ACEI or ARB use was independently associated with respiratory failure or death.

Overall, inclusion of 17 studies from this search update does not change the certainty of evidence rating we reported in the original article for key questions 1 or 2. Although there is a signal toward improved outcomes among patients with COVID-19 who continue use of ACEIs or ARBs, the benefits and harms of initiating ACEIs or ARBs (that is, new users) in COVID-19 treatment remains unclear. Citation Update A study by Bean and colleagues that was included in our original manuscript as a preprint has now been published (20).

Also of note, we attempted to register our review protocol with PROSPERO, but registration was not accepted given the stage of our review at the time. We followed standard methods and reporting guidelines for systematic reviews (21, 22) . We have posted a copy of our protocol to OSF (https: //osf.io/qm6h9/).

Risks and impact of angiotensinconverting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. A living systematic review

Decreased mortality of COVID-19 with reninangiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Mortality in COVID-19 patients treated with ACEIs/ ARBs: re-estimated meta-analysis results following the Mehra et al. retraction

Ramipril in high-risk patients with COVID-19

Renin-angiotensin-aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study

The effects of ARBs, ACEIs, and statins on clinical outcomes of COVID-19 infection among nursing home residents

This article was published at Annals.org on 26

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensinaldosterone system inhibitors

Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension

Compliance of antihypertensive medication and risk of coronavirus disease 2019: a cohort study using big data from the Korean National Health Insurance Service

Continued in-hospital ACE inhibitor and ARB use in hypertensive COVID-19 patients is associated with positive clinical outcomes

Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: a hospitalbased retrospective cohort study

COVID-19, ACEI/ARBs and gastrointestinal symptoms: the jury is still out on the association

Long-term ACE inhibitor/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center

Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Comparative impacts of ACE (angiotensinconverting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF

Annals of Internal Medicine 1